

MULTI-OMICS TEMPORAL PROFILING OF AXIAL SPONDYLOARTHRITIS PATIENTS REVEALS AN ASSOCIATION OF THERAPEUTIC RESPONSE TO ADALIMUMAB WITH DISEASE ACTIVITY AND INNATE / ADAPTIVE IMMUNITY

Daniel Sobral^{1,2}, Ana F Fernandes³, Atlas Sardoo⁴, Miguel Bernardes^{5,6}, Patrícia Pinto⁷, Helena Santos^{4,8}, João Lagoas-Gomes⁹, José Tavares-Costa¹⁰, José AP Silva^{11,12}, João M Dias^{4,13}, Alexandra Bernardo⁶, Jean-Charles Gaillard¹⁴, Jean Armengaud¹⁴, Vladimir Benes¹⁵, Lúcia Domingues^{4,16}, Nélia Gouveia^{4,17}, Sara Maia^{4,17}, Jaime C Branco^{4,18}, Ana V Coelho³, Fernando M Pimentel-Santos^{4,18,*}

¹ Associate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal

² UCIBIO – Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal

³ Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal

⁴ CEDOC, FCM|Nova Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal

⁵ Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal

⁶ Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal

⁷ Rheumatology Department, Hospital Centre of Vila nova de Gaia espinho, Vila nova de Gaia, Porto, Portugal

⁸ Portuguese Institute of Rheumatology, Lisboa, Portugal

⁹ Rheumatology Department, Centro Hospitalar do Tâmega e Sousa, Hospital Padre Américo, Penafiel, Portugal

¹⁰ Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal

¹¹ i.CBR – Institute for Clinical and Biomedical Research, Faculty of Medicine, University of Coimbra, Portugal.

¹² Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Portugal.

¹³ Rheumatology Department, Centro Hospitalar Médio Tejo, Torres Novas, Portugal

¹⁴ Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 30200 Bagnols sur Cèze, France

¹⁵ EMBL Genomics Core Facility, Meyerhofstr. 1, D-69117 Heidelberg

¹⁶ Escola Superior de Saúde – Instituto Politécnico de Setúbal, Setúbal, Portugal

¹⁷ NOVA Clinical Research Unit of Universidade Nova de Lisboa, Lisboa, Portugal

¹⁸ Rheumatology Department, CHLO, Hospital de Egas Moniz, Lisboa, Portugal

* Corresponding author: pimentel.santos@nms.unl.pt

ABSTRACT

Background: Axial Spondyloarthritis can lead to significant disability and impairment in quality of life. TNF inhibitors are recommended to patients enduring active disease despite conventional treatment. Nonetheless, up to 40% of patients fail to respond to TNF inhibitors. In this context, it is important to identify as early as possible patients highly likely to respond. This study aims at identifying, among axial spondyloarthritis patients undergoing treatment with the TNF inhibitor adalimumab, early molecular biomarkers differentiating good responders from non-responders after 14 weeks of treatment, as measured by ASAS20.

Methods: Peripheral blood RNA sequencing and serum proteins measured by mass spectrometry were evaluated in a cohort of biologic naïve axial spondyloarthritis patients (n = 35), before (baseline) and after (3-5 days, 2 weeks and 14 weeks) treatment with adalimumab. Results from differential expression analysis were used in combination with clinical data to build logistic regression models and random forest models to predict response to adalimumab at baseline.

Results: Responders to adalimumab presented higher levels of markers of innate immunity at baseline, mostly related with neutrophils, and lower levels of adaptive immunity markers, particularly B-cells. A logistic regression model incorporating ASDAS-CRP and AFF3, the top differentially expressed gene between responders and non-responders at baseline, enabled an accurate prediction of response to adalimumab in our cohort (AUC=0.96), with random forest models suggesting 80% predictive accuracy. A treatment-associated signature suggests a reduction in inflammatory activity, with C-reactive protein and Haptoglobin showing strong and early decrease in the serum of axial spondyloarthritis patients, while a cluster of apolipoproteins showed increased expression at week 14.

Conclusions: Differences in disease activity and/or blood innate/adaptive immune cell type composition at baseline may be a major contributor to response to adalimumab in axial spondyloarthritis, where a model including clinical and blood gene expression variables shows high predictive power. Our results suggest novel molecular biomarkers of response to adalimumab at baseline.

Trial registration: Axial spondyloarthritis patients were selected from participants of the Bioefficacy study - Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing

Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry (clinical trials.gov identifier NCT02492217).

Keywords: Axial spondyloarthritis, TNF inhibitor, Adalimumab, Treatment response, Disease activity, Innate immune system, Adaptive immune system, Peripheral blood, RNA sequencing, Proteomics.

BACKGROUND

Axial Spondyloarthritis (axSpA) can lead to significant disability and impairment in quality of life [1]. Inflammatory back pain is a characteristic symptom, and new bone formation with syndesmophytes and ankylosis are the disease radiographic hallmarks. Clinical features of axSpA are heterogeneous, including inflammatory back pain, asymmetrical peripheral oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such as acute anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Pulmonary, renal, neurological, aortic root involvement and conduction abnormalities are all rare complications of axSpA [2].

In axSpA, non-steroidal anti-inflammatory drugs (NSAIDs) have a central role in treatment and are considered the first-choice drug treatment. However, biological disease-modifying antirheumatic drugs (bDMARDs) including TNF inhibitors (TNFi), are recommended to patients enduring active disease despite conventional treatment (or intolerance/contraindication) [3]. The efficacy of TNFi has been documented in several studies showing significant and early improvements in disease activity and function [4] sustainable for long periods of time [5]. In spite of its well documented benefit in axSpA, up to an estimated 40% axSpA patients fail to respond to TNFi treatment [6] or complain with adverse events [7].

The concept of “window of opportunity” is of critical importance in rheumatoid arthritis (RA) [8] and seems to be also relevant in the axSpa context, with studies of magnetic resonance

imaging in the context of TNFi treatment suggesting that early effective suppression of inflammation has the potential to reduce radiographic damage [9]. Patients that fail to respond to the first bDMARD usually switch to another bDMARD (with the same or other mechanism of action, such as IL-17 inhibitors [10]), and it may take several iterations to find a drug that reduces disease activity [3]. Response to an effective therapy can take several weeks/months, and the delay caused by non-response may imply irreversible damage. In this context, it is important to identify as early as possible the patients highly likely to respond, meaning to achieve remission or low disease activity, following the treat to target concept [11].

Studies specifically in axSpA indicate that primary non-responders to TNFi tend to be older, HLA-B27 negative, with longer disease duration (> 20 years), higher structural damage and poor function [12]. Likewise, good response to therapy was associated with younger age, HLA-B27 carriage, short disease duration (<10 years), elevation of acute phase reactants (CRP), and marked spinal inflammation (detectable by MRI) [13]. Higher levels of CRP is the most common marker associated with good response, but higher levels of other inflammation markers such as IL6 [14] and calprotectin [15] have also been associated with positive outcomes of TNFi treatment.

The molecular characterization of anti-TNF response in axSpA revealed the unsurprising involvement of genes related with immunity and inflammation [16,17]. Although several studies address the overall effect of TNFi treatment in the axSpA context [18], very few specifically address the molecular changes associated with response/non-response to anti-TNF treatment in axSpA, most of them focusing on specific markers of inflammation in the sera of a limited set of patients. In particular, no study systematically assessed large scale transcriptomics and/or proteomics data to find early predictors of response to anti-TNF in axSpA. On the other hand, several studies have tried to develop such predictors in RA, with variable success [19–21]. One study using whole blood transcriptomics achieved 65% accuracy of response to infliximab in RA

with a 10-gene biomarker set [19]. In another study using transcriptomics of monocytes, CD11c was found to be a very good predictor of response (95% accuracy) to adalimumab monotherapy in RA [20]. Thomson and colleagues used publicly available data to develop a model including 18 signaling mechanisms that could increase the capacity to discover non-responders, from 27% to 59% [21]. More recently, several studies suggested an interplay between innate and adaptive immunity, with a higher myeloid-driven inflammation in responders and higher lymphoid activity in non-responders [21–23].

Reliable predictors of outcome for anti-TNF monotherapies in axSpA are currently not yet available. The goal of this study is thus the identification of baseline predictors, using transcriptomic and proteomic approaches, of patient response to anti-TNF therapy (adalimumab) in axSpA using peripheral blood samples, which are particularly appealing given the relative ease of obtaining samples as part of patient follow-up.

METHODS

Study design and samples collection

AxSpa patients were selected from participants of the Bioefficacy study - Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry (clinical trials.gov identifier NCT02492217). This is a multicentric, prospective, nonrandomized, 14-weeks study that includes axSpA adult patients according to axSpA ASAS criteria [24]. The study included biologic naïve patients, starting TNFi therapy with adalimumab (40mg subcutaneously fortnightly), according to the Portuguese Society of Rheumatology Guidelines [25] (see supplementary material). Clinical evaluations and peripheral blood collections were performed at baseline (start bDMARD), and

after 3-5 days, 2 weeks and 14 weeks. Patients were classified as responders and non-responders, according to ASAS20 [26,27] at week 14. To have 80% power to detect a 0.5SD difference between groups at $p=0.05$ (paired t-test), we estimated that we would need samples from 18 responders and 18 non-responders. Usually only 60% of patients after starting TNFi reach ASAS20, which means that we would need to include a larger number of patients to establish the subgroups for analysis. Thus, we included the number of patients necessary to ensure 18 non-responders, after which we closed the recruitment period. All clinical evaluations were performed by previously trained rheumatologists. Blood samples were collected from all subjects at baseline to test for HLA-B27 status and at each timepoint to determine C-reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR), other biochemical parameters and for RNA-seq and serum proteomic analysis.

RNA preparation and NGS sequencing (RNA-seq)

Peripheral blood samples were collected into PAXgene Blood RNA System® tubes and stored at -80°C according to the manufacturer's recommendations [28]. Total RNA was extracted from whole blood samples according to the standard PAXgene protocol (Qiagen, 2008). The quantity of RNA was measured using a NanoDrop 2000/2000c Spectrophotometer according to the manufacturer's procedure (Thermo-Scientific, 2000); RNAs with a 260:280 ratio of ≥ 1.5 were sequenced as below. The quality and quantity of the libraries was assessed by Fragment Analyzer with the method of DNF-474-22 - HS NGS Fragment 1-6000bp (Agilent). Sequencing library preparation was performed using Illumina TruSeq stranded mRNA library preparation kits, with 100ng of total RNA as input. Libraries were sequenced on an Illumina NextSeq500 sequencer (average of 39 million reads per sample, 75 base-pair paired-end). Sample correspondence between timepoints was confirmed using SmaSH [29]. We also used the transcriptomic data to confirm gender and HLA-B27 status.

RNA-Seq data analysis

Raw sequencing reads were aligned to gencode (v32) transcripts using kallisto (version 0.46.1) [43], reaching an average of 86% reads assigned to genes (gene counts are in Supp. Table 11). The edgeR R package was used to filter low-expressed genes with the filterByExpr function and to normalize raw counts with the trimmed mean of M-values (TMM) normalization approach [44]. The limma R package was used to apply a voom transformation for variance stabilization [45], and to obtain differentially expressed genes through an empirical bayes approach. Genes were considered differentially expressed if the adjusted p-value of the test was less than 0.05. Functional enrichment analysis was performed using the fgsea R package, based on ranks of the moderated t-statistic from the empirical bayes analysis. The per-gene variance explained by each variable was estimated using the variancePartition R package. Permutational multivariate analysis of variance (adonis) was performed using the vegan R package.

Inference of Immune cell populations from RNA-Seq data

The hemograms collected in each timepoint were used to correlate with data obtained from transcriptomic analysis. As common hemograms did not provide specific information on B-cells and other more specific cell types, we used Cibersort [30] to infer relative frequencies of immune cell populations by comparing normalized log2(counts per million) of the blood transcriptomes to the Abbas et al. signatures [31]. To assess the accuracy of these measurements, we correlated the relative frequencies obtained with RNA-Seq with the values we obtained with clinical hemograms (Supplemental Figure 8A,B, pearson R=0.84 and p=3.3e-8 for Neutrophils, R=0.86 and p=1.2e-8 for Lymphocytes). For consistency, we used only frequencies from Cibersort estimated values in the analyses for Fig4C and Fig2D, and in logistic regression models. In Supp. Fig. 8C,D we used exclusively hemogram data, and in Supp. Fig. 8E.F we used frequencies estimated with Cibersort confirming the same conclusions.

Quantitative set analysis for gene expression (QUSAGE) [32] was used to assess the fold change of immune signature gene sets from Lewis et al. [33] (Supp. Fig. 7A).

Proteomics Analysis (LC-MS/MS)

Immunoaffinity depletion of high-abundance proteins. Peripheral blood samples were collected into Clot Activator Tubes (Monovette Serum Gel Z- 7.5 mL, Sarsted) containing 100 µL of Protease Inhibitor Cocktail (Sigma-Aldrich). The six most abundant proteins in serum were depleted using the Multiple Affinity Removal Spin Cartridge Human 6 Kit (Agilent Technologies®) following manufacturer's instructions. The remaining proteins were concentrated using 4 mL Spin Concentrators with 5000 MWCO (Agilent Technologies®). A centrifugation was performed (with a fixed angle rotor) at 4000 x g and 10°C until the sample reached a volume between 100 and 140 µL, after which it was recovered from the bottom of the concentrator pocket and stored at -20°C until further analysis. In order to quantify the amount of protein in each sample, the QuantiPro™ BCA Kit (Sigma-Aldrich®) was used.

In-gel protein digestion. 50 µg of total proteins was diluted with MilliQ water to a final volume of 20 µL and 10 µL of LDS3X (Invitrogen™ by Life Technologies™) was added, for a final volume of 30 µL. Samples were heated for 5 min at 99°C and briefly centrifuged (16,000 g for 1 min). The whole volume of the supernatant containing the soluble proteins was loaded on a NuPAGE 4-12% Bis-Tris (Invitrogen™ by Life Technologies™) gel and the proteins were subjected to SDS-PAGE electrophoresis for 5 min. After migration, the gels were stained with Coomassie SimplyBlue SafeStain (Invitrogen™ by Life Technologies™) for 5 min and washed with water overnight with gentle agitation. Polyacrylamide bands containing the stained proteome were cut by the limit of gel wells, between the front of migration and the well bottom. Each sample was treated and proteolyzed with trypsin Gold (Promega©) in presence of ProteaseMax detergent (Promega©) as previously described [46]. The final volume of peptide extract was 50 µL.

LC-MS/MS analysis. Tryptic peptides were analyzed with a Q-Exactive™ HF high resolution tandem mass spectrometer (ThermoFisher Scientific™) incorporating an ultra-high-field Orbitrap analyser as previously described [34]. Shortly, 10 µL of the resulting peptide mixtures for each sample were injected in a random order. First, peptides were desalted online on a reverse phase precolumn Acclaim PepMap 100 C18 (5 µm, 100 Å, 300 µm id x 5 mm), and then, they were resolved on a reverse phase column Acclaim PepMap 100 C18 (3 µm, 100 Å, 75 µm id x 500 mm) at a flow rate of 200 nL/min with a 90 min gradient of 4 to 25 % of B in 75 min and 25 to 40% of B in 15 min (being A: 0.1% HCOOH and B: 80% CH₃CN, 0.1% HCOOH). The Q-Exactive HF instrument was operated according to a Top20 data-dependent method consisting in a scan cycle initiated with a full scan of peptide ions in the ultra-high-field Orbitrap analyzer, followed by serial selection of each of the 20 most abundant precursor ions, high energy collisional dissociation and MS/MS scans. Full scan mass spectra were acquired from m/z 350 to 1,500 with a resolution of 60,000. A peptide exclusion list was established for the most abundant immunodepleted proteins: serum albumin (<https://www.uniprot.org/uniprot/P02768>) complement C3 (P01024), alpha-2-macroglobulin (P01023), and apolipoprotein B-100 (P04114), in order to focus the analysis on the other proteins. Each MS/MS scan was acquired with a threshold intensity of 83.000, on potential charge states of 2+ and 3+ after ion selection performed with a dynamic exclusion of 10 sec, maximum Inclusion Time (IT) of 60 ms and an m/z isolation window of 2.0. MS/MS spectra at a resolution of 15.000 were searched using MASCOT 2.5.1 software (Matrix Science) against the Swissprot Human database downloaded in July 2019 (20.432 Homo sapiens protein sequences). The following parameters were used for MS/MS spectra assignation: full trypsin specificity, maximum of two missed cleavages, mass tolerances of 5 ppm on the parent ion and 0.02 Da on the secondary ions, fixed modification of carbamidomethyl cysteine (+57.0215), and oxidized methionine (+15.9949) and deamidated (NQ) (0.9840) as dynamic modifications.

Protein identification and relative quantification. After LC-MS/MS, a bioinformatic analysis was performed where all peptide matches with a MASCOT peptide score below a query identity threshold p-value of 0.05 were filtered and assigned to proteins. A total of 5,453,298 MS/MS spectra were recorded and 1,632,427 spectra were assigned to peptide sequences from the protein database – these peptide spectral matches are listed in Supp. Table 12. A protein identification was considered valid when at least two different non-ambiguous peptides were detected in the whole dataset. False discovery rate (FDR) for proteins was below 1% when applying these rules with the MASCOT decoy search mode. A total of 333 polypeptide sequences were identified based on at least 2 non-ambiguous peptides – from the initially 377 polypeptide sequences identified, 44 contaminant proteins (keratin and keratin associated proteins) were excluded from further analysis. For each validated protein (listed in Supp. Table 12), the number of MS/MS spectra for all detected non-ambiguous peptides or ‘Spectral Count’ (SC) [47] was used as a proxy of their abundances [48]. To further assess the value of SC as a measure of protein abundance, we compared clinically determined CRP levels with CRP levels measured by proteomics, and found these to be highly correlated (Supp. Fig. 9, pearson $R=0.73$, spearman $\rho=0.79$, $p<2e-16$). Differential protein analysis was performed similarly to the transcriptomics, using the SC values as counts.

Data analysis

Descriptive statistics were used to summarize baseline characteristics for responders and non-responders. Two sample Wilcoxon tests (continuous variables) and chi-square tests of association (categorical variables) were used to compare characteristics between responders and non-responders at different timepoints, in particular between baseline and week 14.

Differential gene and protein expression analysis used the limma R package to apply a voom transformation for variance stabilization on normalized expression values, and to obtain differentially expressed genes through an empirical bayes approach, followed by multiple test correction with the Benjamini-Hochberg method. Genes were considered differentially expressed if the adjusted p -value of the test was less than 0.05.

Logistic regression models, and plotting was performed using the R software. Sparse partial least squares discriminant analysis (sPLS-DA) was performed using the mixOmics R package. Random forest models were obtained using the randomForest R package.

RESULTS

The TNF inhibitor adalimumab induced a reduction in disease activity of most axSpa patients

According to the ASAS20 criteria we obtained 18 non-responders, and selected, from the whole cohort, 18 responders matched to non-responders by age and gender (one non-responder was later excluded as it had missing information). Table 1 briefly summarizes the clinical characteristics of this sub-group of 35 patients included in this study. Responders presented higher values of C-reactive protein (CRP) ($p=0.011$) and ASDAS-CRP ($p<0.001$) at baseline (BL). Responders had a higher proportion of HLA-B27 ($p=0.01$), with 83% having the allele against only 41% of non-responders. Disease activity decreased from baseline to week 14 (w14) in both responders (ASDAS-CRP: from 4.2 at baseline to 1.6 at week 14, $p=2e-04$; BASDAI: from 6.5 to 1.9, $p=2e-04$) and non-responders (ASDAS-CRP: from 3.2 to 2.5, $p=5e-04$; BASDAI: from 5.3 to 4.0, $p=6e-03$) (Table 1, Supp. Fig. 1A,B). This suggests that treatment with

TNFi, with a few exceptions, has lowered inflammatory markers and disease activity scores in most patients.

Treatment with adalimumab had a significant impact on the expression of blood cell transcripts and serum proteins of axSpA patients.

Expression levels of blood cell transcripts and abundances of serum proteins in axSpA patients did not clearly separate responders from non-responders in an unsupervised principal component analysis (PCA) at neither BL nor at w14 (Fig. 1A). Nonetheless, serum proteomics showed clear differences between BL and w14 in responders, suggesting an effective impact of adalimumab treatment. Indeed, a sparse partial least squares discriminant analysis (sPLS-DA) supports a separation between BL and W14, for both responders and non-responders, not only in proteomics (Supp. Fig. 2), but also in transcriptomics ($p < 0.05$, Fig. 1B). Permutational multivariate analysis of variance indicates that both time points (3% and 17%) and response groups (2% and 4%) can explain a small but statistically significant ($p < 0.05$) part of the observed global variation both in transcript and protein levels, respectively. Moreover, sPLS-DA analysis supports a separation between responders and non-responders at baseline ($p < 0.01$, Fig. 1C). This suggests that treatment with TNFi had a significant impact in the expression of blood cell transcripts and serum proteins of axSpA patients undergoing treatment with adalimumab. Moreover, it also suggests the existence of detectable differences between responders and non-responders at baseline.

Blood transcriptome data at baseline suggests that response to adalimumab derived from an interplay between innate and adaptive immunity.

We tested for differences in gene expression or protein abundance between responders and non-responders at baseline. No proteins (of 112) were found to be significantly differentially abundant between the two groups at BL (Supp. Table 9), but we could detect 92 (of 18688)

genes (12 with $FC > 2$) differentially expressed between responders and non-responders at BL, with 16 (0 with $FC > 2$) more expressed in responders and 76 (12 with $FC > 2$) more expressed in non-responders (Fig. 2A, Supp. Table 10). Genes more expressed in responders are associated with inflammation, such as neutrophil degranulation and interferon signaling, while genes more expressed in non-responders are associated with lymphocyte activation, namely B-cell activity, and metabolism, namely translation (Fig. 2B). The top differentially expressed genes are *PAX5*, *MS4A1* (CD20), *FCRLA*, *BANK1* and *AFF3*, all associated with B-cells and all significantly more expressed in non-responders at BL (Fig. 2C). Corroborating this observation, estimation of lymphocyte population frequencies using RNA-Seq indicates significantly higher frequencies of B-cells in non-responders at BL (Fig. 2D). Genes associated with B-cells show the strongest overall difference between responders and non-responders at BL. Moreover, there is a significant positive correlation between disease activity and estimated neutrophil frequencies, and a negative correlation between disease activity and estimated B- and T- cell frequencies at BL (Supp. Fig. 7B). Thus, our results suggest that response to adalimumab derives from alterations in the balance between innate and adaptive immunity, indicating an opposing role particularly between neutrophils and B-cells.

Blood transcriptome data improved ability to differentiate responders versus non-responders at baseline

In our cohort, ASDAS-CRP at baseline was significantly ($p=0.011$) associated with response in a multivariate logistic model of association with TNFi response (Fig. 3A). HLA-B27 status was also significant ($p=0.034$), while age at diagnosis and disease duration did not reach statistical significance. ASDAS-CRP was more elevated in responders, with an optimal threshold of 4.15 (100% sensitivity and 50% specificity) when considered in isolation (area under the curve (AUC) = 0.83, Fig. 5B). A model incorporating simultaneously the clinical parameters ASDAS-CRP and HLA-B27 reached an AUC of 0.88. Interestingly, a model replacing HLA-B27 with the ratio

between neutrophils and total lymphocytes (N/L) achieved an AUC of 0.84, hinting at the potential for the use of hemogram data as a simple alternative to predict response to treatment. Finally, we incorporated in our models variables from the transcriptomic data. For this, we chose the most robustly differentially expressed gene between responders and non-responders at baseline, which was *AFF3*, a tissue-restricted nuclear transcriptional activator preferentially expressed in lymphoid tissues. This gene presented the lowest false discovery rate (0.006), and a fold change of 1.9 (higher in non-responders, Fig. 2A,B). Adding the gene expression values of *AFF3* to a logistic regression model including ASDAS-CRP increased the AUC to 0.96 (Fig. 3B). If we choose the second most robust differentially expressed gene (*BANK1*), we reach a similar AUC of 0.94 (not shown). Moreover, a random forest model using ASDAS-CRP, and *AFF3* achieved a predictive accuracy of 80%, better than using ASDAS-CRP alone (60%) or only clinical variables ASDAS-CRP and HLA-B27 (70%). Thus, our results suggest that blood transcriptome data can improve our ability to differentiate responders from non-responders at baseline, and that simple hemogram data can have valuable clinical application.

Transcripts and proteins varying between baseline and week 14 were associated with a decrease in innate immune activity

To assess more concretely the impact of adalimumab treatment, we first looked for differences in gene expression and protein abundance between BL and w14. In responders, 2120 (of 21438) genes (103 genes with fold change (FC) greater than 2) and 41 (of 129) proteins (7 with FC>2) were differentially abundant between BL and w14, of which 1096 genes (41 with FC>2) and 25 proteins (4 with FC>2) were upregulated at w14 (Fig. 4A, Supp. Tables 1,2).

In responders, genes associated with inflammation, particularly neutrophil-driven (such as *DOK3*, *LRG1*, and *MMP9*), tended to be significantly less expressed in blood cells at w14 in comparison to BL, while upregulated genes were associated mostly with translation and other

metabolic processes (eg. *EEF1A1*, *RPL7*, *MRPL1*, Fig. 4B). In agreement with this, serum proteins less abundant at w14 were associated with the activation of the complement system and innate immunity, including the complement factors *CFB* and *CFH*, and complement components *C3*, *C8B* and *C8G* (Fig. 4B, Supp. Table 2). Serum proteins more abundant at w14 were linked with vitamin metabolism, including the apolipoproteins *APOA1*, *APOA2*, and *APOA4*. Given the consistent decrease in expression of Neutrophil and innate immunity markers, we also compared estimated frequencies of different white blood cells between BL and w14. In agreement with the gene expression results, we observe in responders a significant decrease in neutrophil frequency at week 14, and an increase of B cell frequency (Fig. 4C), with a similar pattern observed for other adaptive immune cell populations such as CD4+ T-cells (Supp. Fig. 7A).

In non-responders, no significant differences in blood cell gene expression were found between BL and w14 (Supp. Fig. 3 and Supp. Table 3). Nonetheless, a rank-based gene set enrichment analysis (GSEA) of the transcriptomics data uncovers the same pathways as in responders (Supp. Fig. 4). In non-responders, 16 serum proteins were found differentially expressed (none with $FC > 2$), of which 11 upregulated at w14, including *APOA1*, *CLEC3B*, *CFH* and *RBP4* (Supp. Table 4). No significant pathways are found in the proteomics data. Also, although there is a similar tendency to decrease neutrophil frequency between BL and w14 in non-responders, it does not reach statistical significance in neutrophils nor other immune cell populations (Supp. Fig. 7A).

Genes and proteins differentially abundant between BL and w14 in responders were at more similar levels between the two patient groups at w14 ($p < 0.05$), suggesting preexisting differences at baseline that got attenuated due to treatment (Supp. Fig. 5). In agreement with this observation, we did not find any genes or proteins displaying significantly different behavior between time and response group, suggesting that the action of adalimumab in responders and

non-responders is similar. Overall, these results suggest that transcripts and proteins varying during adalimumab treatment were associated with a decrease in innate immune activity.

Markers of inflammation were already lowered in the serum after 3-5 days of adalimumab treatment, in both responders and non-responders.

To refine our understanding of the temporal response to adalimumab, we performed serum proteomics analysis also at 3-5 days and 2 weeks after beginning of treatment. In responders, among the serum proteins significantly downregulated at w14 in comparison to BL, Haptoglobin (HP), Haptoglobin receptor (HPR) and CRP showed a tendency to decrease already at 3-5 days, further decreasing until 2 weeks (Fig. 5A, Supp. Tables 5,6). These proteins also tended to decrease in non-responders, particularly in the first two weeks (Supp. Fig. 6A-C, Supp. Tables 7,8). Another group of proteins (including CFH and CFB) displayed a mild continuous decrease through time, while genes like C3 and C8A only appeared to decrease noticeably between week 2 and week 14. Among the proteins significantly increasing in w14 in comparison with BL in responders, there was greater heterogeneity, but some, including APOD, APOA2 and PPBP displayed a tendency to increase their abundance already at week 2, including in non-responders (Fig. 5B, Supp. Fig. 6D). Interestingly, the average level of change of these proteins was much milder (maximum FC of 2) when compared to HP, HPR and CRP (FC of 3-5). Thus, our results indicate that some markers of inflammation elevated at baseline were already lowered in the serum of some patients after just 3-5 days of adalimumab treatment.

DISCUSSION

This work documented that adalimumab treatment has a significant effect in transcript expression and protein abundances during the first 14 weeks of treatment. In our axSpA cohort, TNFi treatment seems to lower inflammatory markers in most patients, as observed in previous studies [4] and suggests an interplay between innate and adaptive immunity. Lymphoid markers such as *AFF3*, and Neutrophil/Lymphocyte ratios, emerge as novel differentiating variables between groups and enable highly accurate predictive models.

The main objective of our study was to identify molecular predictors, at BL, of response to TNFi. Our results corroborate ASDAS-CRP as an effective measure to decide, as promptly as possible, about TNFi as a therapeutic option in axSpA. However, the cut-off to predict response to therapy at baseline with maximum sensitivity is 4.1, representing a very high disease activity. Therefore, more variables are necessary for an accurate prediction, particularly in cases of moderate disease activity. Adding HLA-B27 status brought further improvements, while the addition of other variables (age at disease onset, disease duration) didn't seem to add further resolution to the model. The observation of an interplay between innate and adaptive immunity, also reported in previous studies in RA [23], suggest similar mechanisms in both diseases. Our analysis suggests that the ratios between innate/adaptive immune populations, such as neutrophils/lymphocyte ratios deserve further exploration as a simple clinical marker with interest regarding TNFi therapeutic decision. In agreement with this, replacing HLA-B27 with the ratio of neutrophil frequencies over total lymphocytes at BL enabled an accurate model, although it didn't seem to improve over HLA-B27. This suggests a potential clinical interest, particularly when HLA-B27 status is not easily available.

At the transcriptional level, our analysis revealed significant differences in several genes related to B cells (*AFF3*, *CD19*, *MS4A1*, *FCRLA*, *BANK1*, *PAX5*). In fact, the most enriched pathways were associated with B-cell development and activation (genes less expressed in responders), and to a lesser extent, neutrophil and inflammatory activity (eg. *RIPK3*, genes more expressed

in responders). At the proteomic level, we could not detect any protein consistently different at baseline between responders and non-responders. One possible reason may be that B cell proteins are present at too low a level in serum, which combined with the overall heterogeneity of the samples, made these undetectable in our proteomic analysis. We then used RNA-Seq data to estimate frequencies of different white blood cell populations that are not provided in the normal clinical hemogram, such as B-Cells. Our analysis confirmed a higher frequency of neutrophils, and a lower relative frequency of B cells (and of other adaptive immune populations) in responders in comparison with non-responders at baseline. Adding *AFF3*, a B-cell associated gene that was the top differentially expressed gene at BL between responders and non-responders, in a logistic regression model with ASDAS-CRP, enabled a very accurate prediction of response to adalimumab (AUC=0.96). A similarly high predictive capacity was obtained with another B-cell associated gene (*BANK1*) providing further consistency to our results. Moreover, using the same models with robust machine learning methods including cross-validation suggests a predictive capacity of over 80% accuracy, an estimate which is likely to be very conservative given the small size of our cohort.

To provide further insights regarding the molecular mechanisms involved in the differential response to TNFi treatment, we obtained measures of expression for blood transcripts and serum proteins of axSpA patients during 14 weeks of treatment with adalimumab. Our transcriptomics and proteomics data indicate that a significant fraction of the observed variation in gene expression can be explained by treatment time and response status. Moreover, transcripts and proteins with significantly reduced expression between BL and w14 of treatment were associated with inflammation and innate immunity, in agreement with the observed changes in clinical markers of inflammation and scores of disease activity. Taken together, this suggests the existence of clinically relevant information in the data and the potential to uncover early biomarkers of TNFi response.

Our transcriptomic results are in large agreement with previous results in axSpA. Namely, *TNFSF14* (LIGHT), *IL17RA*, and *EPOR*, genes reported by Haroon et al. [16], also had significantly reduced expression after TNFi treatment in our cohort (the gene *IFNAR1* didn't reach significance in our study but had a borderline adjusted p-value of 0.07). Moreover, 58 (16%) of 360 genes upregulated after TNFi in Wang et al. [17] were also upregulated in our study, and 88 (31%) of 285 down regulated genes were also detected in our study (with only one gene showing opposing significant tendencies between the studies). Among the 103 significantly differentially expressed genes (DEGs) between BL and w14 with higher fold changes ($FC > 2$), ten had been previously identified as axSpA-associated in GWAS [35]. Of these, *TNFRSF1A*, *TBKBP1*, *HHAT*, and *LTBR*, all less expressed at w14, are involved in the TNF pathway, mediate apoptosis through nuclear factor- κ B, and function as a regulator of inflammation [36]. Interestingly, *IL1R*, *IL6R* and *TYK2*, more associated with innate immunity, were downregulated, while *IL7R* and *ICOSLG*, more associated with the adaptive immune system, namely the stimulation and differentiation of T and B cells, were upregulated. *FCGR2A*, also downregulated, encodes a cell surface receptor found on phagocytic cells, such as, macrophages and neutrophils. This indicates that, despite heterogeneity in clinical manifestations of axSpA, molecular response to TNFi seems consistent between different studies, at least at the level of the blood cell transcriptome. These results suggest that biomarkers of TNFi response uncovered in our cohort are likely to be generally applicable in the axSpA context, although further validation is still mandatory.

Our study expands on previous works in the axSpA context by introducing proteomics data, including intermediate timepoints during adalimumab treatment. We identified several serum proteins undergoing significant changes in abundance with adalimumab treatment. Overall, we observe a decrease in the abundances of HP, HPR, CRP and complement factors, and an increase of several apolipoproteins, CLEC3b and RBP4. Interestingly, in responders, an early

(since days 3-5) and persistent decrease of HP and CRP is seen, correlating with observed clinical improvement. Decrease of complement factors is milder and occurs later (after week 2). A later increase of apolipoproteins APOA1, APOA2 and APOD, involved in lipid clearance from circulation and anti-inflammatory properties, has been previously shown [37]. Curiously, APOD has no marked similarity to other apolipoprotein sequences, but has a high degree of homology to plasma retinol-binding protein (Rbp), which is also overexpressed, and both are thought to influence bone metabolism [37,38]. Rbp4 seems to be present in a restricted population of epiphyseal chondrocytes and perichondrial cells correlating to the future regions of secondary ossification. In addition, CLEC3B, a plasminogen-binding protein induced during the mineralization phase of osteogenesis, is also more abundant [39]. These data unravel molecular mechanisms underlying the abrogation of inflammation, while also suggesting that osteoproliferation may be induced under TNFi therapy, as documented in recent studies [40–42]. Future studies should aim to uncover the physiopathological role of these genes in TNFi response.

We acknowledge limitations in our study, namely the need for further validation with targeted approaches and in new cohorts. Moreover, as all patients were under adalimumab treatment, we cannot extrapolate the results to other TNFi, although comparison with analysis in RA suggest that the underlying mechanisms will be similar.

CONCLUSIONS

To our knowledge, this study is the first using a multi-omic approach to tackle the difficult challenge of predicting at BL the therapeutic response to TNFi in the axSpA context. Our results suggest an interplay between innate and adaptive immunity occurring under TNFi therapy, with lymphoid markers emerging as the most differentially expressed between groups and enabling highly accurate predictive models with our cohort. In addition, our work confirms transcriptomics results of previous studies investigating the effects of TNFi in axSpA and expands them by

providing a genome-wide census of both blood cell genes expression and serum proteins abundances during the first 14 weeks of treatment with Adalimumab, in both responders and non-responders.

Taken together, our results suggest that molecular data can not only provide mechanistic insights to the genesis and progression of the disease, but also suggest novel biomarkers to evaluate the potential response to adalimumab before initiating treatment or in its initial phases.

DECLARATIONS

Ethics approval and consent to participate:

This study (registered in clinical trials.gov with the identifier NCT02492217) was approved by the national competent authorities: National Ethics Committee for Clinical Research (CEIC) and INFARMED (competent authority to regulate medicinal products). The study was conducted according to Good Clinical Practices (GCP), Declaration of Helsinki, and legal regulation applicable, ensuring participants' safety and mechanisms for data protection. Written informed consent was obtained from all participants before study inclusion. None of the patient identifiers were known to anyone outside of the research group. There was no active involvement of patients or the public as co-producers of research in this project. However, all participants were invited to participate in a meeting where the main results were presented and discussed.

Availability of data and materials

Transcriptomics and proteomics data are available as supplementary tables in zenodo under the DOI <https://doi.org/10.5281/zenodo.4914646>. Mass spectrometry data are available through the ProteomeXchange Consortium via the PRIDE partner repository (<https://www.ebi.ac.uk/pride/>), under dataset identifiers PXD026189 and <http://doi.org/10.6019/PXD026189>.

Competing Interests:

F.M.P.-S. has received research grants by Abbvie, Janssen, Novartis, and received consulting fees from AbbVie, Astra Zeneca, Biogen, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer, Tecnimed, UCB. J.L.-G. received consulting fees from Abbvie, Pfizer. H.S. received consulting fees from Abbvie, Eli-Lilly, Novartis, Pfizer. J.T.-C. received consulting fees from AbbVie, AMGEN, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, UCB. M.B. received consulting fees from Lilly, Janssen and Abbvie. For all authors with potential conflicts of interest, these were not directly related to this study. The other authors declare that there are no conflicts of interest to disclose.

Funding

D.S. was funded by a fellowship from Fundação para a Ciência e Tecnologia (PTDC/MED-ONC/28660/2017). This study was funded by Abbvie but the funder had no influence in study design, data analysis and writing of the submitted document.

Author's Contributions:

Study concept and design: F.M.P.-S., J.C.B.; Acquisition of clinical data: M.B., P.P., H.S., J.L.-G., J.T.-C., J.A.P.S., J.M.D., A.B., S.M., J.C.B., F.M.P.-S.; Laboratorial research direction: A.V.C., F.M.P.-S.; Performance of laboratory experiments: A.S., A.F.F., F.M.P.-S., A.V.C., J.-C.G., J.A., V.B.; Analysis and interpretation of data: D.S., A.V.C., A.F.F., F.M.P.-S.; Writing of the manuscript: D.S., A.V.C., A.F.F., F.M.P.-S.; Critical revision of the manuscript for important intellectual content: All authors.

Acknowledgments

We thank the members of the computational multi-omics group for critical reading of the document. We acknowledge the careful comments provided by 2 anonymous reviewers in a previous submission.

Abbreviations

ASAS: assessment in ankylosing spondylitis

ASDAS: ankylosing spondylitis disease activity score

AUC: area under the curve

axSpA: axial spondyloarthritis

BASDAI: bath ankylosing spondylitis disease activity index

bDMARD: biological disease-modifying antirheumatic drugs

BL: baseline

ESR: erythrocyte sedimentation rate

FC: fold change

GSEA: gene set enrichment analysis

HLA-B27: human leukocyte antigen B27

MRI: magnetic resonance imaging

NSAID: non-steroidal anti-inflammatory drugs

PCA: principal component analysis

RA: rheumatoid arthritis

sPLS-DA: sparse partial least squares discriminant analysis

TNFi: tumor necrosis factor inhibitor

w14: week 14

REFERENCES

- 1 Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis: Curr Opin Rheumatol 2010;22:375–80. doi:10.1097/BOR.0b013e32833ac5cc
- 2 CORPOREA Study Group, Pimentel-Santos FM, Mourão AF, et al. Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts. Clin Rheumatol 2012;31:447–54. doi:10.1007/s10067-011-1854-7
- 3 van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91. doi:10.1136/annrheumdis-2016-210770
- 4 Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNF α blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2015;74:1241–8. doi:10.1136/annrheumdis-2014-205322
- 5 Zochling J, Braun J. Management and treatment of ankylosing spondylitis: Curr Opin Rheumatol 2005;17:418–25. doi:10.1097/01.bor.0000163194.48723.64
- 6 Alazmi M, Sari I, Krishnan B, et al. Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis. Arthritis Care Res 2018;70:1393–9. doi:10.1002/acr.23465
- 7 Chen K, Wei X-Z, Zhu X-D, et al. Whole-blood gene expression profiling in ankylosing spondylitis identifies novel candidate genes that may contribute to the inflammatory and tissue-destructive disease aspects. Cell Immunol 2013;286:59–64. doi:10.1016/j.cellimm.2013.10.009
- 8 Nell VPK. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906–14. doi:10.1093/rheumatology/keh199
- 9 Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther 2014;16:109. doi:10.1186/ar4561
- 10 Blair HA. Secukinumab: A Review in Ankylosing Spondylitis. Drugs 2019;79:433–43. doi:10.1007/s40265-019-01075-3
- 11 Dougados M. Treat to target in axial spondyloarthritis: From its concept to its implementation. J Autoimmun 2020;110:102398. doi:10.1016/j.jaut.2019.102398
- 12 Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2007;67:1276–81. doi:10.1136/ard.2007.073098
- 13 Rudwaleit M. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665–70.

- doi:10.1136/ard.2003.016386
- 14 Pedersen SJ, Sorensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF inhibitors. *Ann Rheum Dis* 2011;70:1375–81. doi:10.1136/ard.2010.138883
- 15 Turina MC, Yeremenko N, Paramarta JE, et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. *Arthritis Res Ther* 2014;16:413. doi:10.1186/s13075-014-0413-4
- 16 Haroon N, Tsui FWL, O'Shea FD, et al. From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. *Ann Rheum Dis* 2010;69:297–300. doi:10.1136/ard.2008.102277
- 17 Wang XB, Ellis JJ, Pennisi DJ, et al. Transcriptome analysis of ankylosing spondylitis patients before and after TNF- α inhibitor therapy reveals the pathways affected. *Genes Immun* 2017;18:184–90. doi:10.1038/gene.2017.19
- 18 Menegatti S, Bianchi E, Rogge L. Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. *Front Immunol* 2019;10:382. doi:10.3389/fimmu.2019.00382
- 19 Tanino M, Matoba R, Nakamura S, et al. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. *Biochem Biophys Res Commun* 2009;387:261–5. doi:10.1016/j.bbrc.2009.06.149
- 20 Stuhlmüller B, Häupl T, Hernandez MM, et al. CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis. *Clin Pharmacol Ther* 2010;87:311–21. doi:10.1038/clpt.2009.244
- 21 Thomson TM, Lescarbeau RM, Drubin DA, et al. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis. *BMC Med Genomics* 2015;8:26. doi:10.1186/s12920-015-0100-6
- 22 Oswald M, Curran ME, Lamberth SL, et al. Modular Analysis of Peripheral Blood Gene Expression in Rheumatoid Arthritis Captures Reproducible Gene Expression Changes in Tumor Necrosis Factor Responders. *Arthritis Rheumatol* 2015;67:344–51. doi:10.1002/art.38947
- 23 Farutin V, Prod'homme T, McConnell K, et al. Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor. *Arthritis Res Ther* 2019;21:216. doi:10.1186/s13075-019-1999-3
- 24 Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009;68:777–83. doi:10.1136/ard.2009.108233
- 25 Machado P, Cerqueira M, Ávila-Ribeiro P, et al. Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. *Acta Reumatol Port* 2017;42:209–18.
- 26 Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. *Arthritis Rheum* 2001;44:1876–86. doi:10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
- 27 Brandt J. Development and preselection of criteria for short term improvement after anti-TNF treatment in ankylosing spondylitis. *Ann Rheum Dis* 2004;63:1438–44. doi:10.1136/ard.2003.016717
- 28 Kruhøffer M, Dyrskjøt L, Voss T, et al. Isolation of Microarray-Grade Total RNA, MicroRNA, and DNA from a Single PAXgene Blood RNA Tube. *J Mol Diagn* 2007;9:452–8. doi:10.2353/jmoldx.2007.060175

- 29 Westphal M, Frankhouser D, Sonzone C, et al. SmaSH: Sample matching using SNPs in humans. *BMC Genomics* 2019;20:1001. doi:10.1186/s12864-019-6332-7
- 30 Chen B, Khodadoust MS, Liu CL, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. In: von Stechow L, ed. *Cancer Systems Biology*. New York, NY: : Springer New York 2018. 243–59. doi:10.1007/978-1-4939-7493-1_12
- 31 Abbas AR, Wolslegel K, Seshasayee D, et al. Deconvolution of Blood Microarray Data Identifies Cellular Activation Patterns in Systemic Lupus Erythematosus. *PLoS ONE* 2009;4:e6098. doi:10.1371/journal.pone.0006098
- 32 Yaari G, Bolen CR, Thakar J, et al. Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations. *Nucleic Acids Res* 2013;41:e170. doi:10.1093/nar/gkt660
- 33 Lewis MJ, Barnes MR, Blighe K, et al. Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. *Cell Rep* 2019;28:2455-2470.e5. doi:10.1016/j.celrep.2019.07.091
- 34 Klein G, Mathé C, Biola-Clier M, et al. RNA-binding proteins are a major target of silica nanoparticles in cell extracts. *Nanotoxicology* 2016;10:1555–64. doi:10.1080/17435390.2016.1244299
- 35 The Australo-Anglo-American Spondyloarthritis Consortium (TASC). Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. *Nat Genet* 2010;42:123–7. doi:10.1038/ng.513
- 36 Hacker H, Karin M. Regulation and Function of IKK and IKK-Related Kinases. *Sci STKE* 2006;2006:re13–re13. doi:10.1126/stke.3572006re13
- 37 White CR, Garber DW, Anantharamaiah GM. Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. *J Lipid Res* 2014;55:2007–21. doi:10.1194/jlr.R051367
- 38 Martineau C, Najyb O, Signor C, et al. Apolipoprotein D deficiency is associated to high bone turnover, low bone mass and impaired osteoblastic function in aged female mice. *Metabolism* 2016;65:1247–58. doi:10.1016/j.metabol.2016.05.007
- 39 Wewer UM, Ibaraki K, Schjørring P, et al. A potential role for tetranectin in mineralization during osteogenesis. *J Cell Biol* 1994;127:1767–75. doi:10.1083/jcb.127.6.1767
- 40 Bruijnen STG, Verweij NJF, van Duivenvoorde LM, et al. Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography. *Rheumatology* 2018;57:631–8. doi:10.1093/rheumatology/kex448
- 41 Gulyás K, Horváth Á, Végh E, et al. Effects of 1-year anti-TNF- α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. *Clin Rheumatol* 2020;39:167–75. doi:10.1007/s10067-019-04771-3
- 42 Boers N, Michielsens CAJ, van der Heijde D, et al. The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review. *Rheumatology* 2019;58:1907–22. doi:10.1093/rheumatology/kez363
- 43 Bray NL, Pimentel H, Melsted P, et al. Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* 2016;34:525–7. doi:10.1038/nbt.3519
- 44 Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol* 2010;11:R25. doi:10.1186/gb-2010-11-3-r25
- 45 Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;43:e47–e47. doi:10.1093/nar/gkv007
- 46 Hartmann EM, Allain F, Gaillard J-C, et al. Taking the shortcut for high-throughput shotgun proteomic analysis of bacteria. *Methods Mol Biol Clifton NJ* 2014;1197:275–85. doi:10.1007/978-1-4939-1261-2_16
- 47 Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. *Nat Biotechnol* 2001;19:242–7.

doi:10.1038/85686

48 Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. *Anal Chem* 2004;76:4193–201.
doi:10.1021/ac0498563

Figure Legends

Figure 1: Response to TNFi has a significant impact on the relative abundance of blood cells transcripts and serum proteins of patients. **A)** Principal Component Analysis (PCA) of the blood cell transcriptomics and proteomics data for responders (R) and non-responders (NL) at baseline (BL) and week 14 (W14). For visual clarity two outliers are out of view in the transcriptomics PCA, but all data was used to generate the plot; **B)** Sparse partial least squares discriminant analysis (sPLS-DA) of transcriptomics data, using time as a variable of interest, in responders (AUC=0.99, permutation test $p=8e-07$) and non-responders (AUC=1, $p=6.4e-07$); **C)** sPLS-DA of transcriptomics (AUC=1, $p=9.6e-07$) and proteomics (AUC=1, $p=3.4e-05$) data at baseline, using response group as a variable of interest. In all cases, AUC and p-value correspond to the two best components of the sPLS-DA. In all graphs, ellipses represent 95% confidence intervals.

Figure 2: Blood transcriptome data at baseline suggests response to adalimumab derives from an interplay between innate and adaptive immunity. **A)** Volcano plot (\log_2 of the fold change versus $-\log_{10}$ of the false discovery rate (FDR)) comparing the transcriptomics responder versus non-responder samples at baseline (Supp. Table 10); **B)** Barplot displaying the Normalized Enrichment Score (NES) of representative significant pathways resulting from a gene set enrichment analysis (GSEA) comparing the gene expression of responder versus non-responder samples at baseline; **C)** Heatmap representation of the expression profile of the top 40 differentially expressed genes comparing responder versus non-responder samples at baseline; for visualization purposes, expression values of each gene were scaled towards a standard distribution (z-score); rows and columns were clustered by correlation; **D)** Estimated B-cell and Neutrophil frequencies in responder and non-responder samples at baseline;

Figure 3: Blood transcriptome data improves ability to differentiate responders versus non-responders at baseline. **A)** Forest plot displaying the logarithm of the odds, 95% confidence interval and p-value of response to adalimumab for different variables from a logistic regression model. **B)** Receiver operating characteristic (ROC) curve displaying specificity and sensitivity for different logistic regression models incorporating: only ASDAS-CRP scores (Area Under the Curve - AUC=0.83); ASDAS-CRP scores and HLA-B27 status (AUC=0.88); ASDAS-CRP scores and the ratio between the estimated frequency of neutrophils and total lymphocytes (N/L, AUC=0.84); ASDAS-CRP and the normalized expression value of *AFF3* (AUC=0.96).

Figure 4: Transcripts and proteins varying between baseline and week 14 were associated with a decrease in innate immune activity. **A)** Volcano plot (\log_2 of the fold change versus $-\log_{10}$ of the false discovery rate (FDR)) comparing the blood cell transcriptomics (Supp. Table 1) and serum proteomics (Supp. Table 2) baseline samples versus week 14 samples in responders; non-significant (NS) genes/proteins are in grey; in green genes/proteins that are not statistically significant ($FDR>0.05$) but have an estimated fold

change greater than 2; in blue genes/proteins that are statistically significant but have a milder fold change (less than 2); in red genes/proteins that are statistically significant and have a fold change greater than 2. All red proteins and some of the red gene names are displayed in the plot. **B)** Barplot displaying the Normalized Enrichment Score (NES) of representative significant pathways resulting from a gene set enrichment analysis (GSEA) comparing the gene expression or protein abundances of w14 (green) against BL (blue) responder samples; **C)** Boxplot displaying estimated Neutrophil or naive B-cell frequencies in BL and w14 samples. In C the p-value is from a paired Wilcoxon rank-sum test; Samples of the same patient are connected with a grey line.

Figure 5: Markers of inflammation are already lowered in the serum after 3-5 days of adalimumab treatment, in both responders and non-responders. A) Log2 fold change of proteins between a given time point and the baseline. Only proteins significantly downregulated at w14 in responders were represented. **B)** Same as A but with upregulated proteins. We clustered proteins with similar temporal behavior using the dtwclust R package. Only the names of a set of representative proteins are displayed.

Table 1. Summary of the clinical characteristics of the cohort. For each continuous variable, the mean and standard deviation within each group were calculated. Two sample Wilcoxon tests (continuous variables) and chi-square tests of association (categorical variables) were used to compare characteristics between “Responders” and “Non-Responders”. Variables include Erythrocyte Sedimentation Rate (ESR, in mm / h), C-Reactive Protein (CRP, in mg / L), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, Bath Ankylosing Spondylitis Functional Index (BASFI) scores, Ankylosing Spondylitis Disease Activity Score (ASDAS) using the ESR levels (ASDAS-ESR) or CRP levels (ASDAS-CRP). For these characteristics, the value at baseline and week 14 is provided, as well as the difference between the two endpoints. Other fixed clinical characteristics include age at diagnosis (in years of age), disease duration (in years since start of first symptoms), presence (Positive) or absence (Negative) of the HLA-B27 allele, and sex (biological gender) – Female or Male.


Figure 1

Group: BL NR BL R W14 NR W14 R


A medRxiv preprint doi: <https://doi.org/10.1101/2022.08.02.22278314>; this version posted August 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Transcriptomics


Proteomics



B Transcriptomics: Baseline versus Week 14




C Responders versus Non-Responders at Baseline




A

Responders versus Non-Responders at Baseline
Transcriptomics



B



D




Figure 3




Figure 4





Figure 5

A medRxiv preprint doi: <https://doi.org/10.1101/2022.08.02.22278314>; this version posted August 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



B Temporal evolution of upregulated plasma proteins




Table 1

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.02.22278314>; this version posted August 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

	NR (N=12) Mean (sd)	R (N=18) Mean (sd)	p value
Erythrocyte Sedimentation Rate (mm / h)			
Baseline	26.059 (20.355)	33.167 (28.461)	0.541
Week 14	11.882 (10.741)	10.833 (9.102)	0.856
BL - W14	14.176 (16.253)	22.333 (23.450)	0.298
C-Reactive Protein (mg / L)			
Baseline	11.312 (11.507)	23.692 (19.678)	0.011
Week 14	7.418 (10.882)	3.896 (2.776)	0.754
BL - W14	3.894 (4.781)	19.796 (19.375)	< 0.001
BASDAI score			
Baseline	5.347 (2.629)	6.528 (1.463)	0.234
Week 14	4.065 (2.181)	1.928 (1.443)	0.003
BL - W14	1.282 (1.502)	4.600 (1.814)	< 0.001
BASFI score			
Baseline	5.291 (2.717)	6.709 (1.906)	0.156
Week 14	3.712 (2.653)	2.548 (2.097)	0.176
BL - W14	1.578 (1.490)	4.161 (2.064)	< 0.001
ASDAS-ESR score			
Baseline	3.229 (0.861)	3.761 (1.083)	0.203
Week 14	2.271 (0.929)	1.478 (0.498)	0.008
BL - W14	0.959 (0.566)	2.283 (1.004)	< 0.001
ASDAS-CRP score			
Baseline	3.159 (0.748)	4.156 (0.756)	< 0.001
Week 14	2.459 (0.753)	1.561 (0.572)	< 0.001
BL - W14	0.700 (0.507)	2.594 (0.940)	< 0.001
Age at Diagnosis (years)			
	37.862 (11.279)	34.851 (11.635)	0.301
Disease duration (years)			
	14.822 (12.742)	13.718 (7.494)	0.869
HLA-B27 Status			
			0.010
Negative	10 (58.8%)	3 (16.7%)	
Positive	7 (41.2%)	15 (83.3%)	
Gender			
			0.915
Female	5 (29.4%)	5 (27.8%)	
Male	12 (70.6%)	13 (72.2%)	